Dublin, Ireland, May 12, 2015 – Inflection Biosciences Ltd, a private company developing highly innovative treatments for cancer, today announced that it will be presenting at BioEquity Europe 2015. The presentation, to be given by Inflection Biosciences’ CEO, Darren Cunningham, will take place during the Next Wave Companies Session at 17.30 on Tuesday May 19th 2015.
BioEquity Europe is the seminal industry event for financial dealmakers looking for investor-validated life science companies positioning themselves to attract capital, and for pharmaceutical licensing professionals to assess top prospects. BioEquity Europe has showcased more than 700 leading European companies to thousands of investment and pharma business development professionals. BioEquity Europe 2015 will be held at the InterContinental Hotel, Vienna, Austria, May 19th-20th, 2015.
About Inflection Biosciences
Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments were licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises IBL-202 (PIM/PI3K inhibitor) and IBL-301 (PIM/PI3K/mTOR inhibitor), selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (highly selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of haematological malignancies and treatment resistant solid tumours. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com